Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus
Randomized, Placebo-controlled, Double-blind, Phase 1, Dose-escalating Study to Evaluate the Safety and Immunogenicity of a Synthetic Virus Like Particle (SVLP) Vaccine Against Respiratory Syncytial Virus (RSV)
Sponsor: Center of Vaccinology, Ghent, Belgium (CEVAC)
Listed as NCT04519073, this PHASE1 trial focuses on Acute Bronchiolitis Due to Respiratory Syncytial Virus and remains completed. Sponsored by Center of Vaccinology, Ghent, Belgium (CEVAC), it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Center of Vaccinology, Ghent, Belgium (CEVAC)
- Expert Clinical Services Organization, Brussels, Belgium (ECSOR)
- Virometix
For direct contact, visit the study record on ClinicalTrials.gov .